DK1463716T3 - Pyrrolidin- og piperidinderivater som NK1-antagonister - Google Patents

Pyrrolidin- og piperidinderivater som NK1-antagonister

Info

Publication number: DK1463716T3
Authority: DK; Denmark
Prior art keywords: pyrrolidine; antagonists; piperidine derivatives; piperidine; derivatives
Prior art date: 2001-12-18

Application number

DK02805167T

Other languages

Danish (da)

English (en)

Inventor

Sunil Paliwal

Gregory A Reichard

Cheng Wang

Juan D Arredondo

Michelle Laci Wrobleski

Dong Xiao

Hon-Chung Tsui

Neng-Yang Shih

Anandan Palani

Original Assignee

Schering Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-12-18

Filing date

2002-12-17

Publication date

2008-06-16

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23337634&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1463716(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2002-12-17 Application filed by Schering Corp filed Critical Schering Corp

2008-06-16 Application granted granted Critical

2008-06-16 Publication of DK1463716T3 publication Critical patent/DK1463716T3/da

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/14—Nitrogen atoms not forming part of a nitro radical
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
- C07D207/50—Nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
- C07D211/28—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms to which a second hetero atom is attached
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
- C07D211/32—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/42—Oxygen atoms attached in position 3 or 5
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D211/74—Oxygen atoms
- C07D211/76—Oxygen atoms attached in position 2 or 6
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/10—Spiro-condensed systems

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Epidemiology (AREA)
Diabetes (AREA)
Psychiatry (AREA)
Addiction (AREA)
Pain & Pain Management (AREA)
Pulmonology (AREA)
Urology & Nephrology (AREA)
Endocrinology (AREA)
Hematology (AREA)
Obesity (AREA)
Hospice & Palliative Care (AREA)
Virology (AREA)
Molecular Biology (AREA)
Otolaryngology (AREA)
AIDS & HIV (AREA)
Tropical Medicine & Parasitology (AREA)
Heart & Thoracic Surgery (AREA)
Rheumatology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Ophthalmology & Optometry (AREA)
Emergency Medicine (AREA)

DK02805167T 2001-12-18 2002-12-17 Pyrrolidin- og piperidinderivater som NK1-antagonister DK1463716T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US34145201P	2001-12-18	2001-12-18
PCT/US2002/040203 WO2003051840A1 (en)	2001-12-18	2002-12-17	Pyrrolidine and piperidine derivates as nk1 antagonists

Publications (1)

Publication Number	Publication Date
DK1463716T3 true DK1463716T3 (da)	2008-06-16

Family

ID=23337634

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK02805167T DK1463716T3 (da)	2001-12-18	2002-12-17	Pyrrolidin- og piperidinderivater som NK1-antagonister

Country Status (35)

Country	Link
US (6)	US7049320B2 (es)
EP (2)	EP1463716B1 (es)
JP (4)	JP4500984B2 (es)
KR (2)	KR20100064394A (es)
CN (1)	CN1606545B (es)
AR (2)	AR037851A1 (es)
AT (2)	ATE522504T1 (es)
AU (1)	AU2002357264B2 (es)
BR (2)	BR0215158A (es)
CA (1)	CA2470476C (es)
CO (1)	CO5590915A2 (es)
CY (2)	CY1108924T1 (es)
DE (1)	DE60225067T2 (es)
DK (1)	DK1463716T3 (es)
EC (1)	ECSP045159A (es)
ES (2)	ES2372871T3 (es)
HK (2)	HK1065036A1 (es)
HU (1)	HUP0402679A3 (es)
IL (2)	IL162484A0 (es)
LT (1)	LTC1463716I2 (es)
LU (1)	LUC00043I2 (es)
MX (1)	MXPA04005910A (es)
MY (2)	MY158859A (es)
NL (1)	NL300895I2 (es)
NO (2)	NO327976B1 (es)
NZ (2)	NZ551997A (es)
PE (1)	PE20030762A1 (es)
PL (1)	PL216664B1 (es)
PT (1)	PT1463716E (es)
RU (1)	RU2326120C9 (es)
SG (1)	SG180017A1 (es)
SI (1)	SI1463716T1 (es)
TW (1)	TWI329511B (es)
WO (1)	WO2003051840A1 (es)
ZA (1)	ZA200404583B (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PE20030762A1 (es) *	2001-12-18	2003-09-05	Schering Corp	Compuestos heterociclicos como antagonistas nk1
ES2285151T3 (es) *	2002-07-03	2007-11-16	Schering Corporation	Derivados de 1-amido-4-fenil-4-benciloximetil-piperidina y compuestos relacionados como antagonistas de neurocinina-1 (nk-1) para el tratamiento de vomitos, depresion ansiedad y tos.
EP1622569B1 (en)	2003-04-24	2015-12-02	Incyte Corporation	Aza spiro alkane derivatives as inhibitors of metallproteases
AU2004308935A1 (en) *	2003-12-22	2005-07-14	Schering Corporation	Pharmaceutical compositions
DE602005025755D1 (de)	2004-06-04	2011-02-17	Teva Pharma	Irbesartan enthaltende pharmazeutische zusammensetzung
ES2632413T3 (es) *	2004-07-01	2017-09-13	Opko Health, Inc.	Derivados de piperidina como antagonistas de NK1
AU2012216435B8 (en) *	2004-07-01	2015-02-19	Opko Health, Inc.	Piperidine derivatives as NK1 antagonists
US7354922B2 (en) *	2004-12-14	2008-04-08	Schering Corporation	Bridged ring NK1 antagonists
US20090264388A1 (en) *	2006-02-22	2009-10-22	Valorisation Recherche Hscm, Limited Partnership	Compounds and Methods of Treating Disorders Associated With Activation of Metachromatic Cells
CL2007000945A1 (es)	2006-04-05	2008-01-25	Schering Corp	Formulacion farmaceutica que comprende una sal cristalina de monohidrato de hidrocloruro de (5s,8s)-8-[[(1r)-1-(3,5-bistrifluorometil)fenil]-etoximetil]-8-fenil-1,7-diaza-espiro[4.5]decan-2-ona; capsula que la contiene; y uso en el tratamiento de la emesis y nausea.
TW200806666A (en) *	2006-04-05	2008-02-01	Schering Corp	Salts of 8-[(1-(3,5-bis-(trifluoromethyl)phenyl)-ethoxy)-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and preparation process therefor
CN101437821B (zh) *	2006-04-05	2014-06-04	欧科生医股份有限公司	8-[{1-(3,5-双-(三氟甲基)苯基)-乙氧基}-甲基]-8-苯基-1,7-二氮杂-螺[4.5]癸-2-酮的盐酸盐及其制备方法
AR066191A1 (es) *	2007-03-22	2009-08-05	Schering Corp	Proceso e intermediarios para la sintesis de compuestos 8- [ ( 1- (3,5- bis- ( trifluorometil) fenil) - etoxi ) - metil]- 8 fenil - 1,7- diaza - espiro (4, 5) decan -2 ona
AR065802A1 (es) *	2007-03-22	2009-07-01	Schering Corp	Formulaciones de comprimidos que contienen sales de 8- [( 1- ( 3,5- bis- (trifluorometil) fenil) -etoxi ) - metil) -8- fenil -1, 7- diaza- spiro [ 4,5] decan -2- ona y comprimidos elaborados a partir de estas
US7786146B2 (en) *	2007-08-13	2010-08-31	Valeant Pharmaceuticals International	Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators
US8138168B1 (en)	2007-09-26	2012-03-20	Takeda Pharmaceutical Company Limited	Renin inhibitors
WO2010028232A1 (en) *	2008-09-05	2010-03-11	Schering Corporation	Process and intermediates for the synthesis of 8-[{1-(3,5-bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one compounds
KR101834577B1 (ko)	2009-08-14	2018-03-05	옵코 헬스, 인크.	뉴로키닌-1 길항제의 정맥내 제형
US8581454B2 (en) *	2010-01-11	2013-11-12	Pro-Dex, Inc.	Handheld device with thermal padding
WO2013004766A1 (en)	2011-07-04	2013-01-10	Ferrari Giulio	Nk-1 receptor antagonists for treating corneal neovascularisation
EP2545905A1 (en)	2011-07-11	2013-01-16	Britannia Pharmaceuticals Limited	A new therapeutical composition containing apomorphine as active ingredient
WO2013168176A2 (en) *	2012-03-30	2013-11-14	Glenmark Generics Limited	Process for preparation of fosaprepitant and salt thereof
CN105017251B (zh) *	2015-06-30	2018-06-29	齐鲁制药有限公司	一种nk-1受体拮抗剂的制备方法及其中间体
WO2017044693A1 (en)	2015-09-11	2017-03-16	Chase Pharmaceuticals Corporation	Muscarinic combination and its use for combating hypocholinergic disorders of the central nervous system
CN105367510B (zh) *	2015-11-02	2017-07-21	叶海伟	一种(2R，4S)‑3‑Cbz‑2，4‑二苯基‑1，3‑恶唑烷‑5‑酮的制备方法
JOP20190077A1 (ar)	2016-10-10	2019-04-09	Array Biopharma Inc	مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret
CN108148060B (zh) *	2016-12-05	2020-06-19	四川科伦博泰生物医药股份有限公司	取代的杂环化合物及其衍生物，其药物组合物、制备方法及用途
BR112019021125A2 (pt)	2017-04-10	2020-05-12	Chase Therapeutics Corporation	Combinação de antagonista de nk1 e método para tratamento de sinucleinopatias
EA202090180A1 (ru)	2017-06-30	2020-05-26	Чейс Терапьютикс Корпорейшн	Композиции nk1-антагониста и способы лечения депрессии
WO2019122068A1 (en) *	2017-12-21	2019-06-27	Intervet International B.V.	Oral pharmaceutical composition of an nk-1 antagonist
US20210015834A1 (en)	2018-02-26	2021-01-21	Ospedale San Raffaele S.R.L.	Nk-1 antagonists for use in the treatment of ocular pain
WO2020257364A1 (en)	2019-06-17	2020-12-24	DeepMap Inc.	Nearest neighbor search using compressed octrees representing high definition maps for autonomous vehicles
EP3991730A4 (en)	2019-06-28	2023-08-09	Shanghai Shengdi Pharmaceutical Co., Ltd	NEUROKININ-1 ANTAGONIST
CA3147543A1 (en) *	2019-07-25	2021-01-28	Intervet International B.V.	Crystalline form of telmapitant or (5r,8s)-8-[[(1r)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]methyl]-8-phenyl-1,3,7-triazaspiro[4.5]decane-2,4-dione
US20230134843A1 (en)	2020-03-11	2023-05-04	Ospedale San Raffaele S.R.L.	Treatment of stem cell deficiency
WO2021198255A1 (en)	2020-04-03	2021-10-07	Nerre Therapeutics Limited	An nk-1 receptor antagonist for treating a disease selecting from sepsis, septic shock,, acute respiratory distress syndrome (ards) or multiple organ dysfunction syndrome (mods)
MX2022014901A (es)	2020-06-02	2023-01-18	Nerre Therapeutics Ltd	Antagonistas del receptor de neuroquinina (nk)-1 para su uso en el tratamiento de condiciones de fibrosis pulmonar promovidas por lesion mecanica a los pulmones.
CN111606868B (zh) *	2020-06-23	2023-02-17	温州大学新材料与产业技术研究院	一种双齿噁唑啉手性配体的制备方法
MX2023007578A (es)	2020-12-25	2023-07-06	Shanghai Shengdi Pharmaceutical Co Ltd	Uso del compuesto profarmaco antagonista nk1 en combinacion con un antagonista del receptor 5-ht3.
IL313428A (en) *	2021-12-22	2024-08-01	Univ California	Covalent binding inhibitors of G12S, G12D and/or G12E mutants of K-RAS GTPASE

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1994010165A1 (en)	1992-10-28	1994-05-11	Merck Sharp & Dohme Limited	4-arylmethyloxymethyl piperidines as tachykinin antagonists
JPH08504435A (ja)	1992-12-14	1996-05-14	メルクシヤープエンドドームリミテツド	タキキニン受容体拮抗剤としての４−アミノメチル／チオメチル／スルホニルメチル−４−フェニルピペリジン
AU685212B2 (en)	1994-01-13	1998-01-15	Merck Sharp & Dohme Limited	Gem-disubstituted azacyclic tachykinin antagonists
ES2181868T3 (es)	1995-02-28	2003-03-01	Aventis Pharma Inc	Composicion farmaceutica para compuestos de piperidinoalcanol.
GB9601680D0 (en)	1996-01-27	1996-03-27	Pfizer Ltd	Therapeutic agents
CA2287397A1 (en)	1997-04-24	1998-10-29	Merck Sharp & Dohme Limited	Use of an nk-1 receptor antagonist and an ssri for treating obesity
US6380242B1 (en) *	1998-12-23	2002-04-30	Nps Allelix Corp.	N-alkylamino-indoles for the treatment of migraine
CO5261559A1 (es) *	1999-12-17	2003-03-31	Schering Corp	Antagonistas de neurokinina selectivos
US6436928B1 (en) *	1999-12-17	2002-08-20	Schering Corporation	Selective neurokinin antagonists
US6499984B1 (en)	2000-05-22	2002-12-31	Warner-Lambert Company	Continuous production of pharmaceutical granulation
ATE374183T1 (de) *	2001-11-13	2007-10-15	Schering Corp	Nk1-antagonisten
PE20030762A1 (es)	2001-12-18	2003-09-05	Schering Corp	Compuestos heterociclicos como antagonistas nk1
ES2285151T3 (es) *	2002-07-03	2007-11-16	Schering Corporation	Derivados de 1-amido-4-fenil-4-benciloximetil-piperidina y compuestos relacionados como antagonistas de neurocinina-1 (nk-1) para el tratamiento de vomitos, depresion ansiedad y tos.
PL1682545T3 (pl)	2003-10-03	2008-04-30	Pfizer	Podstawione imidazopirydyną pochodne tropanu o aktywności antagonisty receptora ccr5 do leczenia hiv i stanu zapalnego
ES2632413T3 (es) *	2004-07-01	2017-09-13	Opko Health, Inc.	Derivados de piperidina como antagonistas de NK1
US7354922B2 (en)	2004-12-14	2008-04-08	Schering Corporation	Bridged ring NK1 antagonists
CL2007000945A1 (es)	2006-04-05	2008-01-25	Schering Corp	Formulacion farmaceutica que comprende una sal cristalina de monohidrato de hidrocloruro de (5s,8s)-8-[[(1r)-1-(3,5-bistrifluorometil)fenil]-etoximetil]-8-fenil-1,7-diaza-espiro[4.5]decan-2-ona; capsula que la contiene; y uso en el tratamiento de la emesis y nausea.
CN101437821B (zh)	2006-04-05	2014-06-04	欧科生医股份有限公司	8-[{1-(3,5-双-(三氟甲基)苯基)-乙氧基}-甲基]-8-苯基-1,7-二氮杂-螺[4.5]癸-2-酮的盐酸盐及其制备方法
AR065802A1 (es)	2007-03-22	2009-07-01	Schering Corp	Formulaciones de comprimidos que contienen sales de 8- [( 1- ( 3,5- bis- (trifluorometil) fenil) -etoxi ) - metil) -8- fenil -1, 7- diaza- spiro [ 4,5] decan -2- ona y comprimidos elaborados a partir de estas

2002
- 2002-12-12 PE PE2002001200A patent/PE20030762A1/es active IP Right Grant
- 2002-12-16 MY MYPI20064327A patent/MY158859A/en unknown
- 2002-12-16 MY MYPI20024703A patent/MY136697A/en unknown
- 2002-12-16 AR ARP020104877A patent/AR037851A1/es not_active Application Discontinuation
- 2002-12-16 TW TW091136267A patent/TWI329511B/zh not_active IP Right Cessation
- 2002-12-17 NZ NZ551997A patent/NZ551997A/en not_active IP Right Cessation
- 2002-12-17 SG SG2006047914A patent/SG180017A1/en unknown
- 2002-12-17 AT AT07118674T patent/ATE522504T1/de active
- 2002-12-17 US US10/321,687 patent/US7049320B2/en active Active
- 2002-12-17 SI SI200230671T patent/SI1463716T1/sl unknown
- 2002-12-17 AT AT02805167T patent/ATE386023T1/de active
- 2002-12-17 PL PL370841A patent/PL216664B1/pl unknown
- 2002-12-17 NZ NZ532975A patent/NZ532975A/en not_active IP Right Cessation
- 2002-12-17 DE DE60225067T patent/DE60225067T2/de not_active Expired - Lifetime
- 2002-12-17 HU HU0402679A patent/HUP0402679A3/hu unknown
- 2002-12-17 EP EP02805167A patent/EP1463716B1/en not_active Expired - Lifetime
- 2002-12-17 JP JP2003552727A patent/JP4500984B2/ja not_active Expired - Fee Related
- 2002-12-17 KR KR1020107011989A patent/KR20100064394A/ko not_active Application Discontinuation
- 2002-12-17 ES ES07118674T patent/ES2372871T3/es not_active Expired - Lifetime
- 2002-12-17 EP EP07118674A patent/EP1882686B1/en not_active Expired - Lifetime
- 2002-12-17 AU AU2002357264A patent/AU2002357264B2/en not_active Ceased
- 2002-12-17 ES ES02805167T patent/ES2299637T3/es not_active Expired - Lifetime
- 2002-12-17 PT PT02805167T patent/PT1463716E/pt unknown
- 2002-12-17 DK DK02805167T patent/DK1463716T3/da active
- 2002-12-17 CA CA2470476A patent/CA2470476C/en not_active Expired - Lifetime
- 2002-12-17 CN CN028255615A patent/CN1606545B/zh not_active Expired - Fee Related
- 2002-12-17 RU RU2004122109/04A patent/RU2326120C9/ru not_active IP Right Cessation
- 2002-12-17 KR KR1020047009445A patent/KR100984617B1/ko active IP Right Grant
- 2002-12-17 BR BR0215158-8A patent/BR0215158A/pt not_active IP Right Cessation
- 2002-12-17 WO PCT/US2002/040203 patent/WO2003051840A1/en active Application Filing
- 2002-12-17 MX MXPA04005910A patent/MXPA04005910A/es active IP Right Grant
- 2002-12-17 IL IL16248402A patent/IL162484A0/xx unknown
- 2002-12-17 BR BRPI0215158-8A patent/BRPI0215158B1/pt unknown
2004
- 2004-06-09 ZA ZA200404583A patent/ZA200404583B/en unknown
- 2004-06-09 CO CO04054290A patent/CO5590915A2/es active IP Right Grant
- 2004-06-13 IL IL162484A patent/IL162484A/en not_active IP Right Cessation
- 2004-06-17 EC EC2004005159A patent/ECSP045159A/es unknown
- 2004-07-16 NO NO20043041A patent/NO327976B1/no not_active IP Right Cessation
- 2004-10-09 HK HK04107784A patent/HK1065036A1/xx not_active IP Right Cessation
- 2004-10-09 HK HK08105913.5A patent/HK1111157A1/xx not_active IP Right Cessation
2006
- 2006-02-21 US US11/358,827 patent/US7902366B2/en not_active Expired - Lifetime
2008
- 2008-04-23 CY CY20081100449T patent/CY1108924T1/el unknown
2009
- 2009-11-10 JP JP2009257558A patent/JP5860199B2/ja not_active Expired - Fee Related
2010
- 2010-12-14 US US12/967,132 patent/US8273895B2/en not_active Expired - Lifetime
2012
- 2012-09-24 US US13/625,799 patent/US8796299B2/en not_active Expired - Lifetime
2013
- 2013-11-08 AR ARP130104108A patent/AR093413A2/es unknown
- 2013-11-29 JP JP2013246864A patent/JP5823476B2/ja not_active Expired - Fee Related
2014
- 2014-07-25 US US14/341,097 patent/US9688693B2/en not_active Expired - Lifetime
2015
- 2015-03-04 JP JP2015042609A patent/JP2015110657A/ja not_active Withdrawn
2017
- 2017-06-23 US US15/631,613 patent/US20170283434A1/en not_active Abandoned
- 2017-10-11 NL NL300895C patent/NL300895I2/nl unknown
- 2017-10-11 LU LU00043C patent/LUC00043I2/en unknown
- 2017-10-11 CY CY2017030C patent/CY2017030I1/el unknown
- 2017-10-16 LT LTPA2017032C patent/LTC1463716I2/lt unknown
- 2017-10-19 NO NO2017053C patent/NO2017053I1/no unknown

Also Published As

Publication number	Publication date
TWI329511B (en)	2010-09-01
HK1065036A1 (en)	2005-02-08
JP4500984B2 (ja)	2010-07-14
MY136697A (en)	2008-11-28
KR20100064394A (ko)	2010-06-14
SG180017A1 (en)	2012-05-30
MY158859A (en)	2016-11-15
BRPI0215158B1 (pt)	2017-06-27
CY1108924T1 (el)	2014-07-02
IL162484A0 (en)	2005-11-20
NL300895I2 (nl)	2017-11-21
HUP0402679A3 (en)	2011-05-30
SI1463716T1 (sl)	2008-06-30
EP1463716B1 (en)	2008-02-13
IL162484A (en)	2012-05-31
ATE522504T1 (de)	2011-09-15
LUC00043I2 (es)	2017-12-20
RU2326120C9 (ru)	2008-11-20
NO20043041L (no)	2004-07-16
WO2003051840A1 (en)	2003-06-26
US9688693B2 (en)	2017-06-27
JP2014058549A (ja)	2014-04-03
US20060199815A1 (en)	2006-09-07
CA2470476A1 (en)	2003-06-26
AU2002357264A1 (en)	2003-06-30
JP2010031053A (ja)	2010-02-12
EP1882686B1 (en)	2011-08-31
LTC1463716I2 (lt)	2018-06-25
US8796299B2 (en)	2014-08-05
DE60225067D1 (de)	2008-03-27
US8273895B2 (en)	2012-09-25
ATE386023T1 (de)	2008-03-15
NZ532975A (en)	2007-02-23
JP2005513068A (ja)	2005-05-12
US20130023503A1 (en)	2013-01-24
CO5590915A2 (es)	2005-12-30
NO2017053I2 (no)	2017-10-19
US7049320B2 (en)	2006-05-23
EP1882686A2 (en)	2008-01-30
CY2017030I2 (el)	2018-04-04
NO327976B1 (no)	2009-11-02
TW200306179A (en)	2003-11-16
CA2470476C (en)	2010-05-25
US7902366B2 (en)	2011-03-08
MXPA04005910A (es)	2004-09-13
US20030158173A1 (en)	2003-08-21
EP1882686A3 (en)	2008-04-30
JP2015110657A (ja)	2015-06-18
KR100984617B1 (ko)	2010-09-30
PT1463716E (pt)	2008-05-12
CN1606545A (zh)	2005-04-13
NO2017053I1 (no)	2017-10-19
LUC00043I1 (es)	2017-10-16
BR0215158A (pt)	2004-10-19
US20140336158A1 (en)	2014-11-13
LTPA2017032I1 (lt)	2017-11-10
CN1606545B (zh)	2013-01-23
ES2372871T3 (es)	2012-01-27
DE60225067T2 (de)	2009-02-05
JP5823476B2 (ja)	2015-11-25
CY2017030I1 (el)	2018-04-04
RU2004122109A (ru)	2005-06-10
JP5860199B2 (ja)	2016-02-16
ES2299637T3 (es)	2008-06-01
RU2326120C2 (ru)	2008-06-10
US20170283434A1 (en)	2017-10-05
PE20030762A1 (es)	2003-09-05
ZA200404583B (en)	2006-02-22
AR093413A2 (es)	2015-06-03
PL370841A1 (en)	2005-05-30
HK1111157A1 (en)	2008-08-01
PL216664B1 (pl)	2014-04-30
ECSP045159A (es)	2004-07-23
AU2002357264B2 (en)	2006-08-24
NZ551997A (en)	2008-07-31
US20110098468A1 (en)	2011-04-28
EP1463716A1 (en)	2004-10-06
AR037851A1 (es)	2004-12-09
HUP0402679A2 (hu)	2005-03-29
KR20040065289A (ko)	2004-07-21

Publication	Publication Date	Title
DK1463716T3 (da)	2008-06-16	Pyrrolidin- og piperidinderivater som NK1-antagonister
NO20015365D0 (no)	2001-11-02	Piperidinderivater som er anvendbare som CCR5-antagonister
NO990551D0 (no)	1999-02-05	Piperidin- og piperazinderivater, og deres anvendelse som muskarine antagonister
NO20026125L (no)	2003-02-04	Tetrahydropyridin- eller piperidin-heterocykliske derivater
NO20040028L (no)	2004-03-04	Substituerte anilinske piperidiner som MCH-selektive antagonister
NO20023485L (no)	2002-09-03	1,3-disubstituerte pyrrolidiner som alfa-2- adrenoceptorantagonister
NO20015366L (no)	2002-01-03	Piperazinderivater som er anvendbare som CCR5-antagonister
AR028343A1 (es)	2003-05-07	Derivados de pirrolidina y piperidina
NO20023787D0 (no)	2002-08-09	Piperazin- og piperidinderivater
ATE308543T1 (de)	2005-11-15	Piperidinderivate
IL160060A0 (en)	2004-06-20	Piperidine derivatives useful as ccr5 antagonists
DK1360184T3 (da)	2005-08-01	Piperidinderivater som neurokinin-1-antagonister
NO20053569D0 (no)	2005-07-21	Substituerte 1-piperidin-4-yl-4-pyrrolidin-3-yl-piperazinderivater og deres anvendelse som nevrokininantagonister
DE60101386D1 (de)	2004-01-15	Piperazin- und piperidinverbindungen
ATE469875T1 (de)	2010-06-15	Nk1-antagonisten
DE60222693D1 (de)	2007-11-08	Nk1-antagonisten
ATE285408T1 (de)	2005-01-15	Paroxetin-n-formyl-derivate
ATE305005T1 (de)	2005-10-15	Piperazinderivative als tachykinin antagonisten
FIU20010313U0 (fi)	2001-08-15	Farmaseuttinen koostumus, joka sisältää amlodipiini maleaattia
FI5469U1 (fi)	2002-07-30	Amlodipiinimaleaatti
GB0104583D0 (en)	2001-04-11	Piperidine derivatives